platinum has been researched along with everolimus in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 32 (91.43) | 24.3611 |
| 2020's | 3 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Barry, JJ; Casey, MA; Feygin, JM; Huibregtse, BA; Pennington, DE; Soucy, NV; Tunstall, R | 1 |
| Allocco, DJ; Dawkins, KD; El-Jack, S; Meredith, IT; Scott, D; Starzyk, RM; Stone, GW; Teirstein, PS; Whitbourn, R; Zambahari, R | 1 |
| Calais, F; Carlsson, J; Götberg, M; James, S; Lagerqvist, B; Nilsson, J; Nilsson, T; Olivecrona, G; Sarno, G; Sjögren, I | 1 |
| Cha, KS; Chae, IH; Hwang, KK; Jeon, HK; Jeong, MH; Kang, SH; Kim, HS; Kim, S; Kwon, HM; Lee, SP; Lee, SY; Moon, KW; Oh, JH; Park, BE; Park, JJ; Park, KW; Park, TH; Rhew, JY; Shin, ES; Yoon, JH | 1 |
| Büttner, HJ; Gick, M; Leibundgut, G; Löffelhardt, N; Neumann, FJ; Toma, A; Valina, C | 1 |
| De la Torre Hernandez, JM; Garcia Camarero, T; Gorria, GM; Lee, DH; Lerena, P; Sainz Laso, F; Zueco, J | 1 |
| Allocco, DJ; Cannon, LA; Dawkins, KD; Dens, J; Dubois, CL; Feldman, RL; Lee, TC; Meredith, IT; Mooney, MR; Pompili, VJ; Rabinowitz, AC; Saito, S; Stone, GW; Teirstein, PS | 1 |
| Choi, D; Hong, MK; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Shin, DH | 1 |
| Allocco, DJ; Dawkins, KD; Fang, Q; Gao, R; Han, Y; Hou, Y; Li, H; Wang, H; Xu, B; Yang, Y; Yu, B; Zhang, J | 1 |
| Garcia-Garcia, HM; Karanasos, A; Regar, E; van Geuns, RJ | 1 |
| Blumenschein, GR; Canales, JR; Ginsberg, LE; Heymach, JV; Kies, MS; Lee, JJ; Lin, H; Lu, C; Massarelli, E; Papadimitrakopoulou, V; Tran, HT; Williams, MD | 1 |
| Chan, KH; Chan, M; Fang, WY; Lee, CH; Li, RG; Low, A; Qu, XK; Richards, AM; Tan, HC | 1 |
| Ando, K; Domei, T; Enomoto, S; Hiromasa, T; Hyodo, M; Iwabuchi, M; Kuramitsu, S; Mazaki, T; Shinozaki, T; Shirai, S; Soga, Y; Yamaji, K | 1 |
| Goto, K; Hagikura, A; Haruta, S; Takebayashi, H | 1 |
| Airaksinen, JK; Karjalainen, PP; Kiviniemi, TO; Mikkelsson, J; Nammas, W; Perälä, A; Pietilä, M; Romppanen, H; Sia, J; Tuomainen, P; Varho, V | 1 |
| Alard, A; Blank, SV; Curtin, JP; David-West, G; Musa, F; Schneider, RJ | 1 |
| Elhadad, S; Fajadet, J; Hildick-Smith, D; Hovasse, T; Neumann, FJ; Petronio, S; Roberts, D; Silber, S; Spence, M; Valdés, M; Wöhrle, J; Zaman, A | 1 |
| Arana, C; Dager, A; Delgado, JA; Gasior, P; Généreux, P; Granada, JF; Hernandez, H; Higuera, S; Maehara, A; Moncada, M; Vesga, B | 1 |
| Byrne, RA; Cassese, S; Colleran, R; de Waha, A; Fusaro, M; Giacoppo, D; Harada, Y; Kastrati, A; Kufner, S; Laugwitz, KL; Ndrepepa, G; Rheude, T; Schunkert, H; Xhepa, E | 1 |
| Boersma, E; Daemen, J; de Jaegere, PP; Diletti, R; Lemmert, ME; Regar, E; van Bommel, RJ; van Domburg, RT; van Geuns, RJ; van Mieghem, NM; Zijlstra, F | 1 |
| Danielewicz, M; Hambraeus, K; James, S; Lagerqvist, B; Lindholm, D; Olivecrona, G; Råmunddal, T; Sarno, G; Varenhorst, C; Witt, N | 1 |
| Allocco, DJ; Chen, J; Dawkins, KD; Fu, G; Han, Y; Hong, T; Jiang, T; Li, H; Liu, H; Pang, W; Su, X; Sun, F; Wang, H; Xu, K; Yang, Y; Yuan, Z; Zhang, J; Zhang, M | 1 |
| Kirtane, AJ; Yancy, CW | 1 |
| Ahn, T; Bae, JH; Cha, KS; Han, KR; Jeon, KH; Kang, HJ; Kim, HS; Kim, SH; Koo, BK; Kwon, HM; Lee, JM; Lee, MS; Oh, SK; Park, KW; Park, SH; Park, WJ; Rha, SW; Rhee, TM; Rhew, JY; Seung, KB | 1 |
| Aizawa, Y; Fujita, S; Fuse, K; Hatada, K; Ikeda, Y; Kishi, S; Matsubara, T; Okabe, M; Sato, T; Takahashi, M | 1 |
| Allocco, DJ; Bouchard, A; Carrié, D; Dawkins, KD; Dens, J; Dubois, CL; Farah, B; Feldman, RL; Hagiwara, N; Kelly, CR; Meredith, IT; Pompili, V; Rabinowitz, A; Saito, S; Stone, GW; Teirstein, PS | 1 |
| Allocco, DJ; Christen, T; Crowley, J; Ferrario, M; Jung, W; Legrand, V; MacCarthy, P; Meredith, IT; Moreno, R; Redwood, S; Richardt, G; Schwimmbeck, P; Ungi, I; Werner, N; Zaman, A | 1 |
| Benito Gonzalez, T; de la Torre Hernandez, JM; Escaned, J; Garcia Del Blanco, B; Gomez Menchero, A; Gonzalo, N; Hernandez, F; Linares, JA; Moreno, R; Rivera, R; Subinas, A; Veiga Fernandez, G | 1 |
| Allocco, D; Aquino, M; Batchelor, W; Claessen, BE; Davis, S; Gigliotti, OS; Giugliano, G; Guedeney, P; Haghighat, A; Horwitz, PA; Kandzari, DE; Lopez, M; Mehran, R; Meredith, IT; Othman, I; Singh, S; Sorrentino, S; Tamis, L; Underwood, P; Wang, JC | 1 |
| Fujii, K; Fujimoto, Y; Himi, T; Ishikawa, K; Kadohira, T; Kitahara, H; Kobayashi, Y; Oka, N; Sano, K; Takahara, M | 1 |
| Allocco, DJ; Amjadi, N; Caputo, C; Chen, H; Kandzari, DE; Meredith, IT; Rowe, SK; Tamboli, HP; Underwood, PL; Williams, J | 1 |
| Cha, KS; Chae, IH; Hur, SH; Hwang, KK; Jeon, HK; Jeong, MH; Kang, J; Kim, CH; Kim, HS; Kim, S; Kwon, HM; Lee, BR; Lee, SY; Moon, KW; Oh, JH; Park, BE; Park, KW; Park, TH; Park, YW; Rhew, JY; Ryu, JK; Shin, ES; Yoon, JH | 1 |
| Asagi, A; Furukawa, M; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Kojima, M; Kojima, Y; Mizuno, N; Murohisa, G; Ohkawa, S; Okusaka, T; Okuyama, H; Shioji, K; Yamanaka, T | 1 |
| Anderson, R; Barragan, P; Bressollette, E; Chun-Chin, C; Hanratty, CG; Kretov, E; Lesiak, M; McEntegart, MB; Menown, I; Merkulov, E; O'Kane, P; Oldroyd, KG; Onuma, Y; Peace, A; Protopopov, A; Rocchiccioli, P; Silvestri, M; van Geuns, RJ; Wlodarczak, A | 1 |
| Asano, T; Garg, S; Ishibashi, Y; Kageyama, S; Katagiri, Y; Kawashima, H; Kogame, N; Kotoku, N; Kozuma, K; Masuda, S; Miyazaki, Y; Morino, Y; Muramatsu, T; Nakamura, M; Nakatani, S; Nakazawa, G; Ninomiya, K; Okamura, T; Onuma, Y; Ozaki, Y; Serruys, PW; Takahashi, H; Takahashi, K; Tanabe, K; Tateishi, H; Tu, S | 1 |
14 trial(s) available for platinum and everolimus
| Article | Year |
|---|---|
The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial.
Topics: Angioplasty, Balloon, Coronary; Chromium; Chromium Alloys; Coronary Stenosis; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Humans; Platelet Aggregation Inhibitors; Platinum; Prospective Studies; Prosthesis Design; Republic of Korea; Research Design; Single-Blind Method; Sirolimus; Time Factors; Treatment Outcome | 2012 |
A real all-comers randomized trial comparing Xience Prime and Promus Element stents.
Topics: Aged; Angina, Stable; Angina, Unstable; Chromium Alloys; Coronary Restenosis; Drug-Eluting Stents; Equipment Failure; Everolimus; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platinum; Sirolimus; Thrombosis; Treatment Outcome | 2013 |
Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions.
Topics: Aged; Cardiovascular Agents; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Europe; Everolimus; Female; Humans; Japan; Male; Middle Aged; New Zealand; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Design; Sirolimus; Time Factors; Treatment Outcome; United States | 2015 |
Randomized comparison of acute stent malapposition between platinum-chromium versus cobalt-chromium everolimus-eluting stents.
Topics: Aged; Cardiovascular Agents; Chromium Alloys; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Design; Republic of Korea; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2015 |
PLATINUM China: a prospective, randomized investigation of the platinum chromium everolimus-eluting stent in de novo coronary artery lesions.
Topics: Adult; Aged; Cardiovascular Agents; China; Chromium; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platinum; Prospective Studies; Prosthesis Design; Single-Blind Method; Time Factors; Treatment Outcome | 2015 |
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Survival Rate | 2015 |
Early vascular healing after titanium-nitride-oxide-coated stent versus platinum-chromium everolimus-eluting stent implantation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Chromium; Coated Materials, Biocompatible; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Finland; Fractional Flow Reserve, Myocardial; Humans; Hyperplasia; Male; Microcirculation; Middle Aged; Neointima; Nitric Oxide; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Single-Blind Method; Time Factors; Titanium; Tomography, Optical Coherence; Treatment Outcome; Vascular Resistance; Vasodilator Agents; Wound Healing | 2016 |
Twelve-month results of a prospective, multicentre trial to assess the everolimus-eluting coronary stent system (PROMUS Element): the PLATINUM PLUS all-comers randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Treatment Outcome | 2017 |
Outcomes of patients treated with durable polymer platinum-chromium everolimus-eluting stents: a meta-analysis of randomised trials.
Topics: Aged; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platinum; Polymers; Treatment Outcome | 2017 |
A randomised comparison of biodegradable polymer- and permanent polymer-coated platinum-chromium everolimus-eluting coronary stents in China: the EVOLVE China study.
Topics: Adolescent; Adult; Aged; China; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platinum; Polymers; Sirolimus; Treatment Outcome; Young Adult | 2017 |
Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial.
Topics: Aged; Asia; Cardiovascular Agents; Chromium Alloys; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Europe; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platinum; Proportional Hazards Models; Prosthesis Design; Risk Factors; Time Factors; Treatment Outcome; United States | 2017 |
Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent - 3-Year Outcomes From the HOST-ASSURE Randomized Clinical Trial.
Topics: Aged; Chromium; Chromium Alloys; Coronary Angiography; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Failure; Sirolimus | 2019 |
A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Neuroendocrine; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pancreatic Neoplasms; Platinum; Progression-Free Survival; Prospective Studies | 2020 |
Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial.
Topics: Absorbable Implants; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platinum; Polymers; Treatment Outcome | 2022 |
21 other study(ies) available for platinum and everolimus
| Article | Year |
|---|---|
Strut tissue coverage and endothelial cell coverage: a comparison between bare metal stent platforms and platinum chromium stents with and without everolimus-eluting coating.
Topics: Angioplasty, Balloon, Coronary; Animals; Chromium; Coronary Vessels; Drug-Eluting Stents; Endothelial Cells; Everolimus; Female; Immunosuppressive Agents; Metals; Microscopy, Electron, Scanning; Platelet Endothelial Cell Adhesion Molecule-1; Platinum; Prosthesis Design; Rabbits; Sirolimus; Stents | 2010 |
PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses.
Topics: Aged; Angioplasty, Balloon, Coronary; Chromium; Coronary Angiography; Coronary Stenosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Platinum; Prospective Studies; Sirolimus; Ultrasonography, Interventional | 2011 |
Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Topics: Aged; Angioplasty, Balloon, Coronary; Chromium; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Platinum; Registries; Sirolimus; Sweden; Treatment Outcome | 2013 |
Longitudinal compression of the platinum-chromium everolimus-eluting stent during coronary implantation: predisposing mechanical properties, incidence, and predictors in a large patient cohort.
Topics: Aged; Cardiovascular Agents; Chi-Square Distribution; Chromium; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Equipment Failure Analysis; Everolimus; Female; Humans; Logistic Models; Male; Materials Testing; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platinum; Prosthesis Design; Prosthesis Failure; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Stress, Mechanical; Tomography, Optical Coherence; Treatment Outcome | 2013 |
Fate of side-branch jailing and a malapposed platinum marker after resorption of an everolimus-eluting bioresorbable vascular scaffold: serial optical coherence tomography observations.
Topics: Absorbable Implants; Angina, Stable; Cardiovascular Agents; Coated Materials, Biocompatible; Coronary Angiography; Coronary Vessels; Everolimus; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platinum; Predictive Value of Tests; Prosthesis Design; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2015 |
Comparison of platinum chromium everolimus-eluting stent with cobalt chromium everolimus-eluting stent in unselected patients undergoing percutaneous coronary intervention.
Topics: Aged; Chromium; Cobalt; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platinum; Radiography; Treatment Outcome | 2015 |
Incidence and Clinical Impact of Stent Fracture After PROMUS Element Platinum Chromium Everolimus-Eluting Stent Implantation.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Chromium; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Humans; Incidence; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platinum; Prosthesis Design; Prosthesis Failure; Risk Factors; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Ultrasonography, Interventional | 2015 |
Unintentional extraction of a platinum-chromium everolimus-eluting stent by entanglement with a covered stent.
Topics: Aged; Chromium; Coronary Angiography; Coronary Stenosis; Device Removal; Drug-Eluting Stents; Everolimus; Humans; Immunosuppressive Agents; Male; Platinum; Vascular Calcification | 2016 |
Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Carboplatin; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Cardiovascular Agents; Chromium; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Humans; Lactic Acid; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platinum; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Predictive Value of Tests; Prosthesis Design; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Wound Healing | 2017 |
The Promus Premier everolimus-eluting platinum chromium stent with durable polymer evaluated in a real world all-comer population in Rotterdam cardiology hospital (the P-SEARCH registry).
Topics: Aged; Angina, Stable; Chromium; Cohort Studies; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Netherlands; Percutaneous Coronary Intervention; Platinum; Polymers; Prospective Studies; Registries | 2017 |
Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Topics: Absorbable Implants; Aged; Angioplasty, Balloon, Coronary; Chromium; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Incidence; Male; Platinum; Polymers; Postoperative Complications; Proportional Hazards Models; Prosthesis Design; Registries; Retrospective Studies; Survival Rate; Sweden; Time Factors; Treatment Outcome | 2017 |
Race/Ethnicity-Based Outcomes in Cardiovascular Medicine.
Topics: Drug-Eluting Stents; Ethnicity; Everolimus; Female; Humans; Male; Platinum; White People | 2017 |
Predictors and Long-Term Clinical Outcome of Longitudinal Stent Deformation: Insights From Pooled Analysis of Korean Multicenter Drug-Eluting Stent Cohort.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Agents; Chromium Alloys; Coronary Angiography; Coronary Artery Disease; Databases, Factual; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platinum; Prosthesis Design; Prosthesis Failure; Republic of Korea; Risk Factors; Sirolimus; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2017 |
Comparison of clinical outcomes of coronary artery stent implantation in patients with end-stage chronic kidney disease including hemodialysis for three everolimus eluting (EES) stent designs: Bioresorbable polymer-EES, platinum chromium-EES, and cobalt c
Topics: Absorbable Implants; Aged; Chromium; Cobalt; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Male; Middle Aged; Percutaneous Coronary Intervention; Platinum; Renal Dialysis; Risk Factors; Trace Elements; Treatment Outcome | 2018 |
Clinical outcomes in unselected patients treated with the PROMUS Element platinum-chromium, everolimus-eluting stent: Final five-year results from the PE PROVE Study.
Topics: Cardiovascular Agents; Chromium; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Europe; Everolimus; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Design; Registries; Risk Factors; Time Factors; Treatment Outcome | 2019 |
The Pt-Cr everolimus-eluting stent with bioabsorbable polymer in the treatment of patients with acute coronary syndromes. Results from the SYNERGY ACS registry.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Agents; Chromium; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platinum; Prosthesis Design; Recurrence; Registries; Retrospective Studies; Risk Factors; Spain; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2019 |
Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies.
Topics: Aged; Cardiovascular Agents; Chromium; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Health Status Disparities; Humans; Male; Middle Aged; Minority Health; Myocardial Infarction; Observational Studies as Topic; Percutaneous Coronary Intervention; Platinum; Prosthesis Design; Race Factors; Registries; Retrospective Studies; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; United States | 2019 |
Assessment of strut coverage of everolimus-eluting platinum chromium stent 2 weeks after implantation by optical coherence tomography.
Topics: Absorbable Implants; Aged; Cardiovascular Agents; Chromium; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Humans; Japan; Male; Middle Aged; Neointima; Percutaneous Coronary Intervention; Platinum; Polyesters; Prospective Studies; Prosthesis Design; Tomography, Optical Coherence | 2019 |
Final 5-Year Results in Unselected Patients Implanted With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study).
Topics: Chromium; Combined Modality Therapy; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Platinum; Prospective Studies; Prosthesis Design; Time Factors; Treatment Outcome; United States | 2019 |
Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN).
Topics: Aspirin; Drug-Eluting Stents; East Asian People; Everolimus; Hemorrhage; Humans; Japan; Percutaneous Coronary Intervention; Pilot Projects; Platinum; Polymers; Prasugrel Hydrochloride; Prospective Studies | 2023 |